DRMA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 18.50%

Insider Buying (Last 12 Months): $1,270.00

Insider Selling (Last 12 Months): $0.00

Dermata Therapeutics Insider Trading History Chart

Dermata Therapeutics Share Price & Price History

^$1.22

▲ +0.02 (1.67%)

As of 03/17/2026 05:00 PM ET

Days: 30 | 90 | 365

Dermata Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/17/2026	Munera Maria E Bedoya-Toro	SVP	Buy	1,000	$1.27	$1,270.00	1,012

SEC Filings (Institutional Ownership Changes) for Dermata Therapeutics (NASDAQ:DRMA)

8.67% of Dermata Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Dermata Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/16/2026	Clear Street Group Inc.	17,000	$39K	0.0%	N/A	0.599%
11/17/2025	Armistice Capital LLC	81,654	$0.41M	0.0%	-74.7%	11.973%
8/14/2025	Armistice Capital LLC	322,179	$0.19M	0.0%	-21.6%	50.498%
5/15/2025	Armistice Capital LLC	411,000	$0.44M	0.0%	+1,411.0%	6.813%
8/15/2024	Armistice Capital LLC	28,000	$67K	0.0%	N/A	4.982%
2/13/2024	Armistice Capital LLC	218,000	$0.13M	0.0%	N/A	6.158%
11/13/2023	Acadian Asset Management LLC	75,538	$79K	0.0%	+34.2%	2.368%
8/7/2023	Acadian Asset Management LLC	56,285	$92K	0.0%	N/A	2.405%
7/27/2023	Virtu Financial LLC	32,105	$53K	0.0%	N/A	1.372%
11/7/2022	Virtu Financial LLC	70,808	$37K	0.0%	N/A	0.701%

Data available starting January 2016

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $1.22

$1.18

$1.25

50 Day Range

MA: $1.73

$1.15

$3.08

52 Week Range

Now: $1.22

$1.11

$23.70

Volume

51,332 shs

Average Volume

2,045,150 shs

Market Capitalization

$3.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Who are the company insiders with the largest holdings of Dermata Therapeutics?: Dermata Therapeutics' top insider shareholders include:
Munera Maria E Bedoya-Toro (SVP)
Learn More about top insider investors at Dermata Therapeutics.
Who are the major institutional investors of Dermata Therapeutics?: Dermata Therapeutics' top institutional shareholders include:
Clear Street Group Inc. — 0.60%
Learn More about top institutional investors of Dermata Therapeutics stock.
Which institutional investors are buying Dermata Therapeutics stock?: In the last quarter, DRMA stock was bought by institutional investors including:
Clear Street Group Inc.